Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 6 of 6 entries
Sorted by: Best Match Show Resources per page
Development of Dual ARV-825 and Nintedanib-Loaded PEGylated Nano-Liposomes for Synergistic Efficacy in Vemurafnib-Resistant Melanoma.

Pharmaceutics

Fu Y, Saraswat A, Wei Z, Agrawal MY, Dukhande VV, Reznik SE, Patel K.
PMID: 34371697
Pharmaceutics. 2021 Jul 01;13(7). doi: 10.3390/pharmaceutics13071005.

A novel treatment strategy by co-targeting c-Myc and tumor stroma was explored in vemurafenib-resistant melanoma. BRD4 proteolysis targeting chimera (ARV-825) and nintedanib co-loaded PEGylated nanoliposomes (ARNIPL) were developed to incorporate a synergistic cytotoxic ratio. Both the molecules have extremely...

Cite
Fu Y, Saraswat A, Wei Z, et al. Development of Dual ARV-825 and Nintedanib-Loaded PEGylated Nano-Liposomes for Synergistic Efficacy in Vemurafnib-Resistant Melanoma. Pharmaceutics. 2021;13(7)doi: 10.3390/pharmaceutics13071005.
Fu, Y., Saraswat, A., Wei, Z., Agrawal, M. Y., Dukhande, V. V., Reznik, S. E., & Patel, K. (2021). Development of Dual ARV-825 and Nintedanib-Loaded PEGylated Nano-Liposomes for Synergistic Efficacy in Vemurafnib-Resistant Melanoma. Pharmaceutics, 13(7), . https://doi.org/10.3390/pharmaceutics13071005
Fu, Yige, et al. "Development of Dual ARV-825 and Nintedanib-Loaded PEGylated Nano-Liposomes for Synergistic Efficacy in Vemurafnib-Resistant Melanoma." Pharmaceutics vol. 13,7 (2021). doi: https://doi.org/10.3390/pharmaceutics13071005
Fu Y, Saraswat A, Wei Z, Agrawal MY, Dukhande VV, Reznik SE, Patel K. Development of Dual ARV-825 and Nintedanib-Loaded PEGylated Nano-Liposomes for Synergistic Efficacy in Vemurafnib-Resistant Melanoma. Pharmaceutics. 2021 Jul 01;13(7). doi: 10.3390/pharmaceutics13071005. PMID: 34371697; PMCID: PMC8308940.
Copy Download .nbib Format: NLM
Recent advances in the application of nanomedicine for the treatment of diabetes.

Nanomedicine (London, England)

Vemana HP, Dukhande VV.
PMID: 34983192
Nanomedicine (Lond). 2022 Jan 05; doi: 10.2217/nnm-2021-0338. Epub 2022 Jan 05.

No abstract available.

Cite
Vemana HP, Dukhande VV. Recent advances in the application of nanomedicine for the treatment of diabetes. Nanomedicine (Lond). 2022;doi: 10.2217/nnm-2021-0338.
Vemana, H. P., & Dukhande, V. V. (2022). Recent advances in the application of nanomedicine for the treatment of diabetes. Nanomedicine (London, England), . https://doi.org/10.2217/nnm-2021-0338
Vemana, Hari Priya, and Dukhande, Vikas V. "Recent advances in the application of nanomedicine for the treatment of diabetes." Nanomedicine (London, England) vol. (2022). doi: https://doi.org/10.2217/nnm-2021-0338
Vemana HP, Dukhande VV. Recent advances in the application of nanomedicine for the treatment of diabetes. Nanomedicine (Lond). 2022 Jan 05; doi: 10.2217/nnm-2021-0338. Epub 2022 Jan 05. PMID: 34983192.
Copy Download .nbib Format: NLM
Recent advances in the application of nanomedicine for the treatment of diabetes.

Nanomedicine (London, England)

Vemana HP, Dukhande VV.
PMID: 34983192
Nanomedicine (Lond). 2022 Jan;17(2):65-69. doi: 10.2217/nnm-2021-0338. Epub 2022 Jan 05.

No abstract available.

Cite
Vemana HP, Dukhande VV. Recent advances in the application of nanomedicine for the treatment of diabetes. Nanomedicine (Lond). 2022;17(2):65-69doi: 10.2217/nnm-2021-0338.
Vemana, H. P., & Dukhande, V. V. (2022). Recent advances in the application of nanomedicine for the treatment of diabetes. Nanomedicine (London, England), 17(2), 65-69. https://doi.org/10.2217/nnm-2021-0338
Vemana, Hari Priya, and Dukhande, Vikas V. "Recent advances in the application of nanomedicine for the treatment of diabetes." Nanomedicine (London, England) vol. 17,2 (2022): 65-69. doi: https://doi.org/10.2217/nnm-2021-0338
Vemana HP, Dukhande VV. Recent advances in the application of nanomedicine for the treatment of diabetes. Nanomedicine (Lond). 2022 Jan;17(2):65-69. doi: 10.2217/nnm-2021-0338. Epub 2022 Jan 05. PMID: 34983192.
Copy Download .nbib Format: NLM
Galactose-decorated liver tumor-specific nanoliposomes incorporating selective BRD4-targeted PROTAC for hepatocellular carcinoma therapy.

Heliyon

Saraswat A, Vemana HP, Dukhande VV, Patel K.
PMID: 35036599
Heliyon. 2022 Jan 03;8(1):e08702. doi: 10.1016/j.heliyon.2021.e08702. eCollection 2022 Jan.

This research deals with the development of asialoglycoprotein receptors (ASGPR) directed nanoliposomes incorporating a novel BRD4 (Bromodomain-containing protein 4) protein-targeted PROTAC (Proteolysis Targeting Chimera), ARV-825 (ARV) (GALARV), and to investigate the anticancer efficacy of GALARV for specific delivery in...

Cite
Saraswat A, Vemana HP, Dukhande VV, et al. Galactose-decorated liver tumor-specific nanoliposomes incorporating selective BRD4-targeted PROTAC for hepatocellular carcinoma therapy. Heliyon. 2022;8(1):e08702doi: 10.1016/j.heliyon.2021.e08702.
Saraswat, A., Vemana, H. P., Dukhande, V. V., & Patel, K. (2022). Galactose-decorated liver tumor-specific nanoliposomes incorporating selective BRD4-targeted PROTAC for hepatocellular carcinoma therapy. Heliyon, 8(1), e08702. https://doi.org/10.1016/j.heliyon.2021.e08702
Saraswat, Aishwarya, et al. "Galactose-decorated liver tumor-specific nanoliposomes incorporating selective BRD4-targeted PROTAC for hepatocellular carcinoma therapy." Heliyon vol. 8,1 (2022): e08702. doi: https://doi.org/10.1016/j.heliyon.2021.e08702
Saraswat A, Vemana HP, Dukhande VV, Patel K. Galactose-decorated liver tumor-specific nanoliposomes incorporating selective BRD4-targeted PROTAC for hepatocellular carcinoma therapy. Heliyon. 2022 Jan 03;8(1):e08702. doi: 10.1016/j.heliyon.2021.e08702. eCollection 2022 Jan. PMID: 35036599; PMCID: PMC8749201.
Copy Download .nbib Format: NLM
EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAF.

Pharmaceutics

Fu Y, Rathod D, Abo-Ali EM, Dukhande VV, Patel K.
PMID: 31581483
Pharmaceutics. 2019 Oct 01;11(10). doi: 10.3390/pharmaceutics11100504.

The clinical outcomes of malignant melanoma have improved with the introduction of mitogen-activated protein kinase kinase (MEK) inhibitors. However, off-target toxicities of the MEK inhibitor trametinib (TMB) often result in dose interruption and discontinuation of therapy. The purpose of...

Cite
Fu Y, Rathod D, Abo-Ali EM, et al. EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAF. Pharmaceutics. 2019;11(10)doi: 10.3390/pharmaceutics11100504.
Fu, Y., Rathod, D., Abo-Ali, E. M., Dukhande, V. V., & Patel, K. (2019). EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAF. Pharmaceutics, 11(10), . https://doi.org/10.3390/pharmaceutics11100504
Fu, Yige, et al. "EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAF." Pharmaceutics vol. 11,10 (2019). doi: https://doi.org/10.3390/pharmaceutics11100504
Fu Y, Rathod D, Abo-Ali EM, Dukhande VV, Patel K. EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAF. Pharmaceutics. 2019 Oct 01;11(10). doi: 10.3390/pharmaceutics11100504. PMID: 31581483; PMCID: PMC6836218.
Copy Download .nbib Format: NLM
Recent advances in the application of nanomedicine for the treatment of diabetes.

Nanomedicine (London, England)

Vemana HP, Dukhande VV.
PMID: 34983192
Nanomedicine (Lond). 2022 Jan;17(2):65-69. doi: 10.2217/nnm-2021-0338. Epub 2022 Jan 05.

No abstract available.

Cite
Vemana HP, Dukhande VV. Recent advances in the application of nanomedicine for the treatment of diabetes. Nanomedicine (Lond). 2022;17(2):65-69doi: 10.2217/nnm-2021-0338.
Vemana, H. P., & Dukhande, V. V. (2022). Recent advances in the application of nanomedicine for the treatment of diabetes. Nanomedicine (London, England), 17(2), 65-69. https://doi.org/10.2217/nnm-2021-0338
Vemana, Hari Priya, and Dukhande, Vikas V. "Recent advances in the application of nanomedicine for the treatment of diabetes." Nanomedicine (London, England) vol. 17,2 (2022): 65-69. doi: https://doi.org/10.2217/nnm-2021-0338
Vemana HP, Dukhande VV. Recent advances in the application of nanomedicine for the treatment of diabetes. Nanomedicine (Lond). 2022 Jan;17(2):65-69. doi: 10.2217/nnm-2021-0338. Epub 2022 Jan 05. PMID: 34983192.
Copy Download .nbib Format: NLM
Showing 1 to 6 of 6 entries